After the application of procaterol hydrochloride oral solution was accepted on May 29, 2023, our company had another good news again this week. On June 6, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products Administration. The procaterol hydrochloride oral solution for inhalation, which is independently developed by Beimei Pharmaceutical, its application was accepted.

Procaterol Hydrochloride Oral Solution for Inhalation

This product is mainly used to relieve symptoms of airflow limitation and dyspnea caused by bronchial asthma, chronic bronchitis and chronic obstructive pulmonary disease. Bronchial asthma is a common chronic inflammatory disease of the airways, usually characterized by reversible expiratory airflow restriction, resulting in recurrent wheezing, shortness of breath, chest tightness, and/or cough. There is no cure for asthma and it requires long-term medication. Chronic bronchitis is a common condition in patients with chronic obstructive pulmonary disease, in which patients have a cough that lasts for two years or more and produces sputum(or cough) for more than three months per year.

Procaterol is an adrenergic β2 receptor agonist, which is highly selective for bronchial β2 receptors. Its bronchodilator effect is strong and lasting, and it can effectively relieve the symptoms of dyspnea caused by the above bronchial diseases.

The inhalation solution dosage form is conducive to the rapid and accurate delivery of drugs to the bronchus and lungs, which can quickly exert the antispasmolysis effect and relieve the symptoms of dyspnea of patients. This time, Beimei Pharma applies two specifications of procaterol hydrochloride solution for inhalation to provide appropriate and accurate dose selection for patients of different ages.

About Shenzhen Beimei Pharmaceutical Co., Ltd.

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated. For more information, please visit our website at http://www.beimeiyaoye.com